• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Combination therapies of porcupine inhibition with ruxolitinib, ibrutinib, or belumosudil in murine sclerodermatous GVHD.

作者信息

Hong Xuezhi, Xiao Yanhua, Xu Liyan, Shen Lichong, Neelagar Ranjana, Devakumar Veda, Trinh-Minh Thuong, Liang Minrui, Rius Rigau Aleix, Zhang Yun, Li Yi-Nan, Dees Clara, Györfi Andrea-Hermina, Wolff Daniel, Herr Wolfgang, Schett Georg, Distler Jörg H W, Matei Alexandru-Emil

机构信息

Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany.

Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany.

出版信息

Blood Adv. 2025 Mar 25;9(6):1261-1266. doi: 10.1182/bloodadvances.2024014387.

DOI:10.1182/bloodadvances.2024014387
PMID:39775728
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11950760/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1aaf/11950760/ce0eee60542f/BLOODA_ADV-2024-014387-gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1aaf/11950760/0b5248470582/BLOODA_ADV-2024-014387-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1aaf/11950760/ce0eee60542f/BLOODA_ADV-2024-014387-gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1aaf/11950760/0b5248470582/BLOODA_ADV-2024-014387-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1aaf/11950760/ce0eee60542f/BLOODA_ADV-2024-014387-gr2.jpg

相似文献

1
Combination therapies of porcupine inhibition with ruxolitinib, ibrutinib, or belumosudil in murine sclerodermatous GVHD.在小鼠硬皮病样移植物抗宿主病中，将豪猪抑制与鲁索替尼、伊布替尼或贝利莫司他联合治疗。
Blood Adv. 2025 Mar 25;9(6):1261-1266. doi: 10.1182/bloodadvances.2024014387.
2
Concomitant Ruxolitinib and Ibrutinib for Graft-Versus-Host Disease (GVHD): The First Reported Use in Pediatric Patients.芦可替尼与伊布替尼联合治疗移植物抗宿主病（GVHD）：首次报道用于儿科患者。
Cureus. 2022 Sep 15;14(9):e29195. doi: 10.7759/cureus.29195. eCollection 2022 Sep.
3
Combination ruxolitinib and belumosudil is tolerable and induces responses despite treatment failure as monotherapies.鲁索替尼和贝莫苏迪尔联合使用耐受性良好，尽管作为单一疗法治疗失败，但仍能诱导缓解。
Leuk Lymphoma. 2025 Jan;66(1):131-138. doi: 10.1080/10428194.2024.2409876. Epub 2024 Oct 12.
4
Contemporary Updates in the Prevention and Treatment of Graft-Versus-Host Disease.当代移植物抗宿主病防治的更新进展。
Curr Hematol Malig Rep. 2024 Dec;19(6):246-255. doi: 10.1007/s11899-024-00741-y. Epub 2024 Nov 9.
5
Recent FDA Approvals in the Treatment of Graft-Versus-Host Disease.近期 FDA 批准的移植物抗宿主病治疗药物
Oncologist. 2022 Aug 5;27(8):685-693. doi: 10.1093/oncolo/oyac076.
6
Preclinical evaluation of JAK1/2 inhibition by ruxolitinib in a murine model of chronic graft-versus-host disease.芦可替尼在慢性移植物抗宿主病小鼠模型中对 JAK1/2 抑制的临床前评价。
Exp Hematol. 2021 Jun;98:36-46.e2. doi: 10.1016/j.exphem.2021.03.004. Epub 2021 Apr 1.
7
A Single-center, Real-world Experience of Chronic GVHD Treatment Using Ibrutinib, Imatinib, and Ruxolitinib and its Treatment Outcomes.一项使用依鲁替尼、伊马替尼和芦可替尼治疗慢性移植物抗宿主病的单中心真实世界经验及其治疗结果
Hematol Oncol Stem Cell Ther. 2023 Jul 20;17(1):60-71. doi: 10.56875/2589-0646.1111.
8
Therapeutic Effects of a NEDD8-Activating Enzyme Inhibitor, Pevonedistat, on Sclerodermatous Graft-versus-Host Disease in Mice.NEDD8激活酶抑制剂pevonedistat对小鼠硬皮病移植物抗宿主病的治疗作用
Biol Blood Marrow Transplant. 2017 Jan;23(1):30-37. doi: 10.1016/j.bbmt.2016.10.022. Epub 2016 Nov 1.
9
Novel Treatment for Graft-versus-Host Disease.移植物抗宿主病的新型治疗方法。
Blood Cell Ther. 2021 Nov 25;4(4):101-109. doi: 10.31547/bct-2021-022.
10
Combinatorial inhibition of Tec kinases BTK and ITK is beneficial in ameliorating murine sclerodermatous chronic graft versus host disease.联合抑制 Tec 激酶 BTK 和 ITK 有益于改善小鼠硬皮病慢性移植物抗宿主病。
Bone Marrow Transplant. 2023 Aug;58(8):924-935. doi: 10.1038/s41409-023-02001-8. Epub 2023 May 9.

本文引用的文献

1
Recent FDA Approvals in the Treatment of Graft-Versus-Host Disease.近期 FDA 批准的移植物抗宿主病治疗药物
Oncologist. 2022 Aug 5;27(8):685-693. doi: 10.1093/oncolo/oyac076.
2
Operational tolerance after hematopoietic stem cell transplantation is characterized by distinct transcriptional, phenotypic, and metabolic signatures.造血干细胞移植后的操作耐受性具有独特的转录、表型和代谢特征。
Sci Transl Med. 2022 Feb 23;14(633):eabg3083. doi: 10.1126/scitranslmed.abg3083.
3
Three US Food and Drug Administration-approved therapies for chronic GVHD.
三种美国食品和药物管理局批准的慢性移植物抗宿主病治疗方法。
Blood. 2022 Mar 17;139(11):1642-1645. doi: 10.1182/blood.2021014448.
4
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.芦可替尼治疗糖皮质激素难治性慢性移植物抗宿主病。
N Engl J Med. 2021 Jul 15;385(3):228-238. doi: 10.1056/NEJMoa2033122.
5
ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease.ROCK2 抑制药贝鲁莫舒地尔（KD025）治疗慢性移植物抗宿主病。
J Clin Oncol. 2021 Jun 10;39(17):1888-1898. doi: 10.1200/JCO.20.02754. Epub 2021 Apr 20.
6
Targeting of canonical WNT signaling ameliorates experimental sclerodermatous chronic graft-versus-host disease.靶向经典 WNT 信号通路可改善实验性硬皮病样慢性移植物抗宿主病。
Blood. 2021 Apr 29;137(17):2403-2416. doi: 10.1182/blood.2020008720.
7
Shared and distinct mechanisms of fibrosis.纤维化的共同和独特机制。
Nat Rev Rheumatol. 2019 Dec;15(12):705-730. doi: 10.1038/s41584-019-0322-7. Epub 2019 Nov 11.
8
Targeting TGF-β signaling for the treatment of fibrosis.靶向 TGF-β 信号通路治疗纤维化。
Matrix Biol. 2018 Aug;68-69:8-27. doi: 10.1016/j.matbio.2017.12.016. Epub 2018 Jan 31.
9
Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.伊布替尼用于既往治疗失败后的慢性移植物抗宿主病。
Blood. 2017 Nov 23;130(21):2243-2250. doi: 10.1182/blood-2017-07-793786. Epub 2017 Sep 18.
10
Fibroblast deletion of ROCK2 attenuates cardiac hypertrophy, fibrosis, and diastolic dysfunction.成纤维细胞中ROCK2的缺失可减轻心脏肥大、纤维化和舒张功能障碍。
JCI Insight. 2017 Jul 6;2(13). doi: 10.1172/jci.insight.93187.